• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Biomet swings to Q4 black, pares fiscal 2013 losses

Biomet swings to Q4 black, pares fiscal 2013 losses

July 11, 2013 By Brad Perriello

Biomet swings to Q4 black, pares fiscal 2013 losses

Biomet said it posted black ink during the 4th quarter and cut its losses for fiscal 2013, reporting a 1.0 % decline in large joint reconstruction sales.

The privately held medical device company, which is said to be considering an IPO or sale, is closely watched as a bellwether for the orthopedic market, which has been bedeviled in recent years by falling procedure volumes for hip and knee replacements.

Biomet reported profits of $20.5 million on sales of $783.9 million for the 3 months ended May 31, representing top-line growth of 6.0%. Warsaw, Ind.-based Biomet reported Q4 losses of $389.1 million last year on a nearly $530 million writedown. Excluding that and other 1-time items, adjusted profits were $133.0 million for Q4 2013, up 26.5% compared with $105.1 million in adjusted profits during the same period last year.

For the full fiscal year, losses were $381.7 million on sales of $3.05 billion, for sales growth of 7.6%. Losses declined 16.8% compared with fiscal 2012, according to a press release.

The news helped push share prices up for Biomet’s peers in the orthopedics sector. Wright Medical (NSDQ:WMGI) stock was trading at $27.76 per share as of about 12:20 p.m. today, up 2.2%; shares of Stryker (NYSE:SYK) gained 1.3%, rising to $67.22 apiece; Smith & Nephew (FTSE:SN, NYSE:SNN) rose 1.7% to $58.63 per share; and Zimmer (NYSE:ZMH) shares gained 1.4%, reaching $78.24 each.

"Our combined hip and knee constant currency growth of 2% for the year was generally in line with the market – not to our standard of clear above-market growth, but we’re working on the product introductions that we believe will return us to that standard," president & CEO Jeffrey Binder said in prepared remarks. "We believe that our large-joint reconstructive business provides us with a strong and stable base and we disagree strongly with those who believe that there are few opportunities for innovation and differentiation. We’re working hard to prove the naysayers wrong."

Earlier this month reports surfaced that Biomet’s private equity owners were putting the company up for sale or considering an IPO.

Filed Under: MassDevice Earnings Roundup, News Well, Orthopedics Tagged With: 2012, Biomet, Q2

More recent news

  • Data backs DermaSensor skin cancer detection device
  • GE HealthCare expands digital imaging portfolio with enhanced MIM Encore software
  • Accelus wins FDA clearance for MRI compatibility of FlareHawk spinal implants
  • Presidio wins FDA IDE for ultra-low frequency neuromod, hires new CFO
  • Epiminder study backs implantable EEG tech

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy